BR0212252A - Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero - Google Patents

Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero

Info

Publication number
BR0212252A
BR0212252A BR0212252-9A BR0212252A BR0212252A BR 0212252 A BR0212252 A BR 0212252A BR 0212252 A BR0212252 A BR 0212252A BR 0212252 A BR0212252 A BR 0212252A
Authority
BR
Brazil
Prior art keywords
heart failure
mammal
methods
reduce hypertension
hypertension
Prior art date
Application number
BR0212252-9A
Other languages
English (en)
Portuguese (pt)
Inventor
M A Q Siddiqui
Eduardo Mascareno
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of BR0212252A publication Critical patent/BR0212252A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0212252-9A 2001-08-31 2002-07-23 Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero BR0212252A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/945,192 US6433018B1 (en) 2001-08-31 2001-08-31 Method for reducing hypertrophy and ischemia
PCT/US2002/023444 WO2003020202A2 (en) 2001-08-31 2002-07-23 Method for reducing hypertension and heart failure

Publications (1)

Publication Number Publication Date
BR0212252A true BR0212252A (pt) 2004-09-14

Family

ID=25482762

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212252-9A BR0212252A (pt) 2001-08-31 2002-07-23 Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero

Country Status (11)

Country Link
US (2) US6433018B1 (enExample)
EP (1) EP1427401A4 (enExample)
JP (2) JP2005505545A (enExample)
KR (1) KR20040050894A (enExample)
AU (1) AU2002313700B2 (enExample)
BR (1) BR0212252A (enExample)
CA (1) CA2458798C (enExample)
MX (1) MXPA04001913A (enExample)
NZ (1) NZ531693A (enExample)
WO (1) WO2003020202A2 (enExample)
ZA (1) ZA200402540B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433018B1 (en) * 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US20050038450A1 (en) * 2003-06-03 2005-02-17 Ping Hu Methods and apparatus for minimally invasive transverse aortic banding
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US20050130893A1 (en) * 2003-09-30 2005-06-16 Joan Smith-Sonneborn Use of opioids in prevention of and recovery from a stress-induced crash in blood pressure
PT1701941E (pt) 2003-12-11 2012-08-03 Univ Texas Compostos para o tratamento de doenças proliferativas celulares
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
US7662389B2 (en) * 2003-12-17 2010-02-16 Alcon, Inc. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
US20100113481A1 (en) * 2003-12-17 2010-05-06 Alcon Research, Ltd. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
US8691877B2 (en) * 2004-10-15 2014-04-08 Palo Alto Investors Methods and compositions for treating a disease condition in a subject
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
RU2485106C2 (ru) * 2005-06-08 2013-06-20 Райджел Фамэсьютикэлз, Инк. Соединения, проявляющие активность в отношении jak-киназы (варианты), способ лечения заболеваний, опосредованных jak-киназой, способ ингибирования активности jak-киназы (варианты), фармацевтическая композиция на основе указанных соединений
US10517876B2 (en) 2005-11-16 2019-12-31 Cti Biopharma Corp. Oxygen linked pyrimidine derivatives
CN101365703B (zh) 2005-11-16 2013-11-06 S*Bio私人有限公司 杂烷基连接的嘧啶衍生物
US20100242139A1 (en) * 2006-01-13 2010-09-23 President And Fellows Of Harvard College Xenohormesis based compositions and methods
US8962643B2 (en) * 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
AU2007220047B2 (en) * 2006-02-28 2013-08-01 Ym Biosciences Australia Pty Ltd Inhibition of JAK2 as a treatment of pulmonary arterial hypertension
BRPI0709916B8 (pt) * 2006-03-31 2021-05-25 Univ Texas drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
HRP20170317T1 (hr) * 2008-02-15 2017-04-21 Rigel Pharmaceuticals, Inc. Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza
PT2323993E (pt) 2008-04-16 2015-10-12 Portola Pharm Inc 2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8258144B2 (en) * 2008-04-22 2012-09-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
NZ590372A (en) 2008-07-08 2012-09-28 Univ Texas Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
MX2011006206A (es) 2008-12-11 2011-07-20 S Bio Pte Ltd Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26- triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5 ,8,10,12(27),16,21,23-decaeno.
CA2768543C (en) * 2009-07-28 2017-06-20 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
JP5275966B2 (ja) * 2009-12-21 2013-08-28 パナソニック株式会社 繊維ボードの製造方法
EP2975027A1 (en) 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
US8877760B2 (en) 2011-11-23 2014-11-04 Portola Pharmaceuticals, Inc. Substituted pyrazine-2-carboxamide kinase inhibitors
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
EP2903970A4 (en) 2012-10-08 2016-11-30 Portola Pharm Inc SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
TW202134236A (zh) 2014-06-12 2021-09-16 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA2012634A1 (en) * 1990-03-20 1991-09-20 Hassan Salari Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US6255296B1 (en) 1994-01-11 2001-07-03 Endomatrix, Inc. Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
US6358954B1 (en) 1999-11-09 2002-03-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
US6433018B1 (en) * 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
DE602006000402T8 (de) * 2006-06-02 2009-04-09 Teva Pharmaceutical Industries Ltd. Stabile Zubereitung enthaltend eine feuchtigkeitsempfindliche aktive Substanz und Verfahren zur Herstellung der Zubereitung.

Also Published As

Publication number Publication date
WO2003020202A2 (en) 2003-03-13
EP1427401A4 (en) 2009-04-29
ZA200402540B (en) 2005-06-29
US7235588B2 (en) 2007-06-26
JP2005505545A (ja) 2005-02-24
AU2002313700B2 (en) 2007-04-26
MXPA04001913A (es) 2004-06-18
US20040266661A1 (en) 2004-12-30
WO2003020202A3 (en) 2003-08-28
KR20040050894A (ko) 2004-06-17
JP2010285455A (ja) 2010-12-24
US6433018B1 (en) 2002-08-13
CA2458798C (en) 2013-06-25
CA2458798A1 (en) 2003-03-13
NZ531693A (en) 2006-05-26
EP1427401A2 (en) 2004-06-16

Similar Documents

Publication Publication Date Title
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
BR0107705A (pt) Uso de uma alìquota de sangue modificado em um paciente para tratamento de falência cardìaca congestiva
MXPA03006855A (es) Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion.
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
DK0950057T3 (da) 3-pyridylenantiomerer og deres anvendelse som analgetika
BR0315597A (pt) Processos de baixa dose para tratamento de distúrbios em que a atividade de tnf(alfa)é prejudicial
ES2164916T3 (es) Tratamiento de la esclerosis multiple.
SE9702860D0 (sv) New use
NO20010844L (no) Regulering av substrataktivitet
BR0110420A (pt) Agonistas muscarìnicos
BRPI0408784A (pt) método para usar um composto
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
PL370795A1 (en) Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DK0986393T3 (da) Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer
BR0115215A (pt) Método para o tratamento de inflamações
ATE419037T1 (de) Verwendung eines mittel zur therapie der herzhypertrophie
DE60305534D1 (de) Verwendung von docosahexaensäure als wirkstoff bei der behandlung von lipodystrophie
BR0315374A (pt) Compostos orgânicos
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
BR0308517A (pt) Combinação de um antagonista do receptor de aldosterona e de um agente sequestrante de ácido biliar
SE0100873D0 (sv) Method of treatment
MY118982A (en) Method of reducing tissue damage associated with ischemia
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica
BR0308105A (pt) Composição farmacêutica compreendendo um bisfosfonato e um inibidor de cox-2 para o tratamento de doenças de ossos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2316 DE 26-05-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.